The Promise of Potent and Durable Immunity

October 2023

Gritstone bio, Inc.

LEGAL DISCLAIMER

Safe Harbor and Forward-Looking Statements

This presentation contains forward-looking statements including, but not limited to, statements related to Gritstone bio, Inc.'s ("Gritstone", "we" or "our") proprietary drug candidates, including GRANITE, SLATE and CORAL, the timing of the start, conclusion and status of ongoing or planned clinical trials, including the timing of, and our ability to achieve, anticipated milestones, the sufficiency of our cash, cash equivalents and short-term investments, availability of funding, business strategy, the timing and outcome of regulatory decisions, future availability of pre-clinical and clinical trial data, our collaborations for our product candidates and the maintenance of those collaborations; business and results from operations; and other matters. Forward-looking statements generally contain words such as "believes," "expects," "may," "will," "should," "seeks," "approximately," "intends," "plans," "estimates," "anticipates," and other expressions that are predictions of or indicate future events and trends and that do not relate to historical matters. Because forward-looking statements are inherently subject to risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.

The forward-looking statements in this presentation are based on information available to Gritstone as of the date this presentation. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to our business in general, see Gritstone's most recent Annual Report on Form 10-K filed on March 9, 2023 and any subsequent current and periodic reports filed with the Securities and Exchange Commission.

This presentation also contains estimates and other statistical data made by independent parties and by us relating to market size and growth and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. In addition, projections, assumptions, and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk.

This presentation concerns drugs that are under clinical investigation and which have not yet been approved for marketing by the U.S. Food and Drug Administration. They are currently limited by Federal law to investigational use, and no representation is made as to their safety or effectiveness for the purposes for which they are being investigated.

ABOUT GRITSTONE

Developing Next-Generation Vaccines for Oncology and Infectious Disease

Platforms Drive More Potent and Durable Immunity

Best-in-class antigen prediction

Proprietary, next-gen vectors drive response

Fully-integrated Biomanufacturing

Potential best-in-class neoantigen-based personalized cancer vaccine program (GRANITE) in randomized Phase 2/3 study for MSS-CRC

Self-amplifying mRNA (samRNA) candidate for COVID-19 in BARDA-funded, 10,000 subject Phase 2b randomized head-to-head study against currently-approved vaccine

Upcoming data readouts could de-risk clinical platforms and potentially enable expansion into additional disease types

Anticipated Upcoming Milestones

Additional data from COVID-19 Phase 1 studies (Oct 2023)
Preliminary data from Phase 2/3 GRANITE-1L study (1Q 2024)
Initiate Phase 2b head-to-head study in COVID-19 (1Q 2024)

Estimated Cash Runway into 4Q 2024*

**based on cash, cash equivalents, marketable securities, and restricted cash as of June 30, 2023 as well as estimated fees receivable and anticipated reimbursement of certain direct and indirect costs to Gritstone (during 4Q 2023 and the first half of 2024 under the BARDA Contract announced on September 27, 2023*

OUR CAPABILITIES

Pursuing More Potent and Durable Immunity Through Vaccine Innovation

Capabilities uniquely designed to address current vaccine challenges



Proprietary artificial intelligence platform (EDGE™) to identify critical T cell targets

Next-gen vectors, ChAd and self-amplifying mRNA*, to drive potent and durable immune responses suited to the clinical context

In-house GMP manufacturing enables personalized and off-the-shelf products (clinical stage and scale-up)

Immunogen design is key component of novel vaccine formats – must be studied in clinical trials

Bench-to-bedside-to-bench: innovative product development pushes scientific boundaries

Gritstone was the first to introduce self-amplifying mRNA (samRNA) + LNP into clinical trials (2018)

OUR VACCINE PIPELINE

EDGE™ Prime-boost samRNA

Disease Area	Target/Approach	Indication	Preclinical	Phase 1	Phase 2	Milestones	Collaborator
Oncology	Individualized Neoantigens	First-line microsatellite-stable colorectal cancer (MSS-CRC)		GRANITE		*1Q2024 Prelim Randomized Ph 2 Data*	
	Shared Neoantigens	KRAS^{mut}-driven tumor types		SLATE		*2024 Initiate Randomized Ph 2**	
	Shared Neoantigens	Solid tumor	SLATE			*Submit IND*	

Disease Area	Target/Approach	Indication	Preclinical	Phase 1	Phase 2	Milestones	Collaborator
ID Prophylaxis	Spike + T Cell Epitopes	SARS-CoV-2 (COVID-19)		CORAL		*1Q2024 Initiate Randomized Ph 2b*	BARDA
	Undisclosed	Multi-respiratory				*Undisclosed*	
	Undisclosed	Influenza				*Undisclosed*	

Disease Area	Target/Approach	Indication	Preclinical	Phase 1	Phase 2	Milestones	Collaborator
ID Therapeutic	HIV Eradication	HIV		HIV		*TBD: Potential Opt-in Program*	GILEAD
	HPV Eradication	HPV				*Undisclosed*	BILL & MELINDA GATES foundation

**Randomized trial in newly-diagnosed metastatic patients*

gritstone bio

GRANITE, SLATE and CORAL are clinical program names

Oncology

Redefining Survival in Solid Tumors

Therapeutic

Neoantigen Cancer Vaccines

Personalized Cancer Vaccines are Ushering in a New Era of Immunotherapy

Potential proof-of-concept for novel modality is rapidly growing, with multiple randomized studies ongoing

- Genomic Sequencing
- Epitope Identification
- Immunogen Payloads
- Delivery Vectors
- "n of 1" Manufacturing

	gritstone bio[1]	BIONTECH	moderna
Tumor Type	**MSS-CRC (1L)** *Cold*	Melanoma (1L) *Hot*	Melanoma (Adj) *Hot*
Neoantigen Training Data	**Proprietary**	Proprietary	Proprietary
Regimen/Vector	**ChAd prime + samRNA boosts** (heterologous, intramuscular)	mRNA[2] prime + boosts (homologous, intravenous)	mRNA[2] prime + boosts (homologous, intramuscular)
CD8+ T cell Priming[3]	**++**[4]	+	+
Data	**Prelim randomized Phase 2 data expected in 1Q'24 (a Phase 2/3 study)**	Randomized Phase 2 data expected in 2H2023	✓ Recurrence-free survival benefit (HR=0.56)

[1]*GRTS vaccine candidates have not been studied head-to-head with those listed.*

[2]*BioNtech uses optimized Uridine mRNA. Moderna uses Modified Uridine mRNA.*

[3]*Semi-quantitative assessment of strength and breadth of human T cell immune response to neoantigen vaccine based on cross-study comparisons of published data*

[4]*CD8 T cell priming: Miao et al., Molecular Cancer 20, 41 (2021)*

Gritstone's Approach: Induce CD8+ T cells Against "Cold" Solid Tumors

Antigen selection + prime-boost regimen may be effective in tumors unresponsive to anti-PD(L)-1 therapy

Low PD-L1

MSS-CRC Tumor cells

anti-PD(L)-1 mAb

Little to no immune response

1 EDGE™

Tumor-specific neoantigens selected

2 Prime

Chimpanzee Adenovirus

3 Boost

Self-amplifying mRNA

Heterologous Prime-boost

De novo Cytolytic CD8+ T cells

Neoantigens delivered via synergistic vectors to enhance potency and durability



gritstone bio

GRANITE: Individualized Neoantigen Vaccine for Solid Tumors

Leveraging neoantigens to transform MSS-CRC into an actionable target*

1

Neoantigen Selection

20

patient-specific neoantigens identified by proprietary AI platform (EDGE™)

2

Heterologous Prime-Boost

ChAd + samRNA

delivery vectors synergize to enhance potency and durability of immunogen payload

3

Selected POC Indication

MSS-CRC

immunologically "cold" tumor with significant unmet need (2nd leading cause of cancer deaths**)

**MSS-CRC = metastatic, microsatellite stable colorectal cancer* ***American Cancer Society's Cancer Statistics Center and Colorectal Cancer Facts & Figures 2020-2022*

GRANITE: Advanced to Randomized Phase 2/3 with Registrational Intent

Positive results in advanced solid tumors (Phase 1/2) provided basis for advancement to first-line MSS-CRC

Phase 1/2 Clinical Takeaways*

Indication: 3L advanced solid tumors (incl. MSS-CRC)

Regimen: GRANITE + nivolumab + ipilimumab

Patient Outcomes:

- Well-tolerated
- Extended survival (22+ months in molecular responders, mOS not reached yet)
- Robust, broad and persistent induction of CD8+ T cells against targeted neoantigens
- 55% (6/11) molecular response by ctDNA reduction with visible lesion shrinkage
- No dose-limiting toxicities (DLTs)

Randomized Phase 2/3 Study

Indication: 1L maintenance in MSS-CRC

Regimen: GRANITE + anti PD-L1+ Fluoropyrimidine + bevacizumab

Endpoints: ctDNA (potential accelerated path) and/or overall survival

Clinical Strategy: Use MSS-CRC as POC to pursue multiple solid tumors

Milestones:

- Received fast-track designation in MSS-CRC (in 2018)
- Preliminary Phase 2 data expected in 1Q 2024

Interim results from Phase 1/2 were published in Nature Medicine

Palmer, C.D., Rappaport, A.R., Davis, M.J. *et al.* Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results. *Nat Med* **28**, 1619–1629 (2022).

GRANITE: Phase 2 Primary Endpoint = Molecular Response (ctDNA)

Change in circulating tumor DNA (ctDNA) increasingly recognized as a clinically meaningful surrogate for survival

Researchers

nature medicine

Genentech

> Overall, measuring ctDNA dynamics during treatment can improve patient risk stratification and may allow early differentiation between competing therapies during clinical trials

A longitudinal circulating tumor DNA-based model associated with survival in metastatic non-small-cell lung cancer (Nature Medicine, March 2023)

Developers

gritstone bio · IMMUNOCORE · natera · AstraZeneca · MERCK · Roche · janssen · NOVARTIS · Pfizer · Takeda · GSK

> ✓ ctDNA better surrogate of OS than RECIST
>
> ✓ KIMMTRAK (FDA-approved for uveal melanoma based on OS) showed significant correlation between ctDNA reduction and extended overall survival

Immunocore Corporate Presentation (November 2022)

Advocates

AACR American Association for Cancer Research

colorectal cancer alliance

FRIENDS of CANCER RESEARCH [1]

> We observed strong associations between reductions in ctDNA levels from on-treatment liquid biopsies with improved overall survival and progression free survival

Changes in Circulating Tumor DNA Reflect Clinical Benefit Across Multiple Studies of Patients With Non-Small-Cell Lung Cancer Treated With Immune Checkpoint Inhibitors (JCO Oncology, August 2022)

FDA Draft Guidance: Use of Circulating Tumor DNA for Early-Stage Solid Tumor Drug Development (May 2022)

[1]*Gritstone bio established partnership with Friends of Cancer Research in August 2023 in support of the ctMoniTR Project*

Phase 1/2 Results: Consistent Induction of Neoantigen-specific T cells

Lack of T cells in patients prior to treatment reflective of poor intrinsic immunogenicity of tumors

T cells as measured by *ex vivo* ELISpot



G5: no samples available (patient died); data represent peak responses post-GRANITE treatment

Phase 1/2 Results: Median Overall Survival in MR Exceeds 22 Months*

FDA has reviewed registrational Phase 2/3 study design with molecular response (MR) as Phase 2 primary endpoint; Phase 3 primary efficacy endpoint TBD

Median Overall Survival in 3L MSS-CRC**



Overall Survival from GRANITE Phase 1/2



[1] *13 MSS-CRC patients treated; 2 did not have samples for analysis of ctDNA changes relative to baseline and included in without MR group; 6 of 11 were molecular responders; Molecular responders defined as patients with ≥30% reduction in ctDNA*

[2] *Mayer et al., The New England Journal of Medicine 372, 1909-1919 (2015)*

[3] *Grothey et al., The Lancet 381, 303-312 (2013)*

**Data cut-off 31-Aug-2022*

***GRTS vaccine candidates have not been studied head-to-head with those listed.*

gritstone bio

GRANITE: Study Design for Randomized Phase 2/3 in 1L MSS-CRC

Study Population	Phase	Primary Endpoint	N
1L MSS-CRC	2	Molecular Response (change in ctDNA)	100[1]
	3	TBD (to be determined following prelim Phase 2 data)	TBD

[1] *Study expanded in May 2023 (from n = 80).*

Induction Chemo
All patients

~4-6 months

Oxaliplatin

(with or without irinotecan)

+

5-FU and bevacizumab

Maintenace treatment stage begins

Control Arm

Continue 5-FU and bevacizumab only

GRANITE

Continue 5-FU and bevacizumab + GRANITE + ipilimumab (x2 doses) + atezolizumab (monthly)

GRANITE = ChAd (Chimpanzee Adenovirus) + self-amplifying mRNA (samRNA)

Atezolizumab previously demonstrated to provide no additional benefit in this patient population (MODUL study[2])

GRANITE regimen ~12 months

gritstone bio

[2] *MODUL study: https://www.esmoopen.com/article/S2059-7029(22)00187-9/fulltext*

Positive Phase 2 Results Could Validate Platform and Support Phase 3 in MSS-CRC

Therapeutic Value Proposition

- Induce existing and de novo T cell response
- Make “cold” tumors actionable via neoantigens
- Personalize treatment to maximize efficacy

GRANITE

personalized cancer vaccine program encoding patient-specific neoantigens

High Unmet Need in Colorectal Cancer*

2nd

leading cause of U.S. cancer deaths in men and women combined

~53,000

deaths expected to occur in 2023[1]



*MSS-CRC is estimated to be 95%+ of all CRC**

**Colorectal cancer statistics per American Cancer Society 2023 Estimates*

Positive Phase 2 Results Could Also Unlock Additional Tumor Types

Success in MSS-CRC could de-risk platform and support expansion to both "cold" and "hot" tumors



SLATE: Off-the-Shelf Neoantigen Vaccines for Solid Tumors

Shared neoantigen program utilizing same antigen selection and vectors as GRANITE

1

Neoantigen Selection

Relevant

Shared neoantigens identified by proprietary AI platform (EDGE™)

2

Heterologous Prime-Boost

ChAd + samRNA

delivery vectors synergize to enhance potency and durability of immunogen payload

3

Solid Tumor Application

Multiple

tumor types addressed via off-the-shelf cassette and streamlined manufacturing

Molecular Response Associated with Prolonged OS in MSS-CRC and NSCLC



1. 39% molecular response rate* and favorable safety profile of SLATE reinforces therapeutic potential of neoantigen approach
2. Phase 2 data further supports the correlation seen between molecular response and overall survival in late-line solid tumors
3. Phase 2 data in late-line patients supports moving KRAS-directed candidate into earlier lines of treatment

[1] Data collected from Phase 1/2 SLATE study (NCT03953235).
**7 of 18 subjects (MSS-CRC and NSCLC) demonstrated molecular response.*

SLATE: Serving Solid Tumor Patients via Shared Neoantigen Immunotherapy



Refined payload of v1 cassette after initial studies indicated immunodominance of non-KRAS antigens

KRAS-dedicated v2 cassette demonstrated Phase 2 proof of concept in MSS-CRC and NSCLC patients

Optimized and validated SLATE cassette now ready for "plug and play" application across solid tumor indications

gritstone bio

CTAs - cancer testis antigens ; HERVs - human endogenous retroviruses; neoORFs - noncanonical open reading frames

Infectious Disease

Leaving no strain behind

Prophylactic

Self-amplifying mRNA Vaccines

Self-amplifying mRNA: Addressing Current Vaccine Limitations for ID

Well-tolerated, scalable platform technology that offers potential advantages over first-generation mRNA



1. **Durable antibody responses** from extended antigen expression enable less frequent boosts

2. **Broad T cell responses** provide second layer of protection and may extend immunity

3. **Dose-sparing regimens** induce equivalent nAb titers at fractional doses of approved SOCs

samRNA Platform

Multiple Pathogens

can be targeted, ranging from respiratory viruses like influenza to sexually transmitted infections such as HPV. Potential to combine into single product.

Gritstone's Differentiated Approach to COVID-19

Novel "Spike-plus" approach designed to drive durable and broad immunity

1st Generation mRNA (Spikevax, Comirnaty)		Gritstone self-amplifying mRNA (CORAL)
nAbs Against Spike Only That Wane After 4-6 Months		Durable nAbs Against Spike; T cells Against Conserved Viral Targets
Spike-specific Immunity Subject to Viral Mutation and Immune Evasion		Broad T cell Immunity May Enable Cross-Variant Protection
High-dose, Repeat Boosts		Low Dose, Durable Response

BARDA: Advancing CORAL to Phase 2b Head-to-Head Study in COVID-19

Contract valued at up to $433 million enables randomized study evaluating Gritstone's samRNA vaccine with a currently-approved mRNA vaccine[1]

Collaborator	N	Randomization	SARS-CoV-2 Variant
	~10,000*	1:1	XBB.1.5

Study Population	Study Arms (Control vs Treatment)		
Previously Vaccinated Healthy Volunteers	Gritstone samRNA Vaccine	VS	FDA-approved COVID-19 Vaccine

* *Estimated study population size; US only*

[1] *Consists of funding for (1) a base period of $10 million for performance of certain milestones such as preparation of protocol synopsis and submission of an investigational new drug application and (2) following successful completion of the base period, approximately $423 million of additional BARDA funding for two stages gated at BARDA's discretion in support of the clinical trial execution and additional analyses for the clinical trial.*

gritstone bio

Phase 1 Studies Providing Proof-of-Concept for Wide Scale Use

Results to date demonstrate potential for broad applicability across patient populations and settings

Study	Population	Vaccine	n	Data to Date
CORAL - BOOST *(United Kingdom)*	Previously-vaccinated healthy volunteers (4 of 6 cohorts ≥60 years)	samRNA boost or samRNA/samRNA	40*	✓ Robust & durable nAbs ✓ Dose sparing potential ✓ T cell induction
CORAL - CEPI *(S. Africa)*	Unvaccinated (virus-naïve or convalescent) healthy volunteers, including people living with HIV	samRNA boost or samRNA/samRNA	342**	✓ Robust & durable nAbs ✓ Dose sparing potential ✓ T cell induction
CORAL - NIH *(United States)*	Previously-vaccinated healthy volunteers	ChAd/samRNA or samRNA/samRNA	150	Data to be presented at IDWeek 2023

***Trial supported by funding from CEPI. Fully enrolled as of February 2023.*
**Original study included n = 20. Gritstone expanded study in January 2022.*

CORAL Phase 1 Collaborators

CEPI

NIH National Institute of Allergy and Infectious Diseases

gritstone bio

Phase 1 Results Highlight Differentiator: Long Lasting Antibody Response

High neutralizing antibody (nAb) levels sustained at 6 months across multiple populations and settings

CORAL-BOOST: Elderly UK Population, samRNA Following Adenoviral or mRNA Primary Series

High nAbs to Spike$_{D614G}$ and VOC Beta, Delta and Omicron BA1 & BA4/5 are maintained following single dose boost

***Post-adenoviral data below. See full poster for post-mRNA data.*



Spike-specific binding neutralizing (nAb) ND50 antibody levels are shown for cohort 1 and 2 subjects receiving a single or two doses of GRT-R910 at 10μg or 30μg. Data from treatment day D1 baseline, 1-month post most recent GRT-R910 dose, and 6-months post most recent GRT-R910 dose. Geomeans with 95% confidence intervals are shown. SARS-CoV-2 negative by PCR at screening.

CORAL-BOOST ECCMID 2023 Poster

CORAL-CEPI: Young, Unvaccinated S. African Population, samRNA as Single Dose or Homologous Prime Boost

High nAb levels to Spike Beta & Delta maintained in previously-unvaccinated subjects



*Spike-specific neutralizing (nAb) ND$_{50}$ antibody levels are shown for naïve (A1 and A2) and convalescent (A4 and A5) subjects receiving one or two doses of GRT-R914 at 3μg or 10μg dose. Geomeans with 95% confidence intervals are shown. *SARS-CoV-2 anti-N IgG seronegative.*

CORAL-CEPI ECCMID 2023 Poster

** Full datasets provided in the respective posters*

gritstone bio

CORAL-CEPI: nAb Durability in Previously Unvaccinated Subjects (Beta and Delta VOCs)

Cross-study 6-month data vs. Moderna and Pfizer shown; vaccines not studied head-to-head directly

Gritstone's samRNA vaccine candidate elicits durable nAb responses against Beta and Delta variants, in contrast to FDA-approved Moderna and BioNtech/Pfizer mRNA vaccines

Adapted from: Evans et al. Sci. Transl. Med. 2022[1]



CORAL-CEPI: Gritstone samRNA[2] (10 µg)



[2] *SARS-CoV-2 naïve (orange): Participants received 2 doses with anti-N seronegative at baseline. nAb data were collected at Day 29 (Post 1st dose), Day 57 (Post 2nd dose), and Day 209 (6 month after last dose). SARS-CoV-2 convalescent (green): Participants received 1 dose with anti-N seropositive at baseline. nAb data were collected at Day 29 (Post 1st dose), Day 57 (2 months post 1st dose), and Day 180 (6 month after last dose). Error bars indicates means ± SEs; the dashed horizontal line indicates the limit of detection (NT50 < 100) for Evan et al. Sci. Transl. Med. 2022. and it is lower limit of quantification (ND_{50} <62) for GO-012 data.*

[1] Evans et al. Sci Transl Med. 2022 Mar

There are limitations in this comparison, such as: a) study populations may not be entirely comparable; b) experience with circulating SARS-CoV-2 may be different; c) assays may not be entirely comparable, d) baseline values may be very different across studies

gritstone bio

CORAL-BOOST: samRNA Boost Elicited Similar nAbs at up to 1/10th the Dose

*Cross-study comparison: 10µg of samRNA elicited similar nAbs as 100µg of Moderna (mRNA-1273) after AZ primary series**

Neutralizing antibodies (geomean) against Wild Type Variant



*Not studied head-to-head directly. ID50 = Median infective dose; Geomean ID50 titer values notated CTRL: Equivalent meningococcal conjugate vaccine; Treatment day = day 1 GRTS samRNA boost dose was administered. Boxes and horizontal bars denote interquartile range (IQR) and median neutralization, respectively. Whisker endpoints are equal to the maximum and minimum values below or above the median +/- 1.5 x IQR.

Phase 1 Results: Robust and Broad CD8+ T cell Induction

samRNA has driven potent cytotoxic cellular responses against both Spike and non-Spike SARS-CoV-2 viral epitopes

CORAL-BOOST: Non-Spike CD8+ T cell responses after single 10ug samRNA boost following Vaxzevria (AstraZeneca) primary series

Proportion of responses to TCE5 regions assessed by post-IVS ELISpot



TCE5 overlapping peptide (OLP) pools to TCE5 Nucleocapsid, Membrane and ORF3a regions assessed by post-IVS ELISpot (post-treatment timepoint)

CORAL-CEPI: Previous SARS-CoV-2 exposure does not affect T cell responses post-vaccination



Frequency of peak T cell responses to TCE components at post- vaccination timepoint are shown for naïve (n=7) and convalescent (n=7) subjects following one or two doses of GRT-R914.

Next Steps: Initiating Phase 2b Head-to-Head Study in COVID-19

Randomized study to further establish differentiation and potential superiority over existing COVID-19 vaccines

Execute BARDA Contract (September 2023)

- Awarded contract to execute head-to-head Phase 2b study
- Contract valued at up to $433 million[1]

Study Planning and Preparation (In Process)

In Process

- Establish comparative vaccine and study design
- Submit and clear IND

Study Initiation (Expected 1Q 2024)

1Q 2024

- Initiate 10,000 participant study, 1:1 randomization
- Enrollment expected to commence in 1Q 2024

Study to be executed in collaboration with:



COVID-19 Prevention Network

gritstone bio

[1] *Consists of funding for (1) a base period of $10 million for performance of certain milestones such as preparation of protocol synopsis and submission of an investigational new drug application and (2) following successful completion of the base period, approximately $423 million of additional BARDA funding for two stages gated at BARDA's discretion in support of the clinical trial execution and additional analyses for the clinical trial.*



Gilead Collaboration

Gritstone bio + Gilead Sciences, Inc.

Therapeutic

Curative Vaccine for HIV

Gilead HIV Cure Collaboration for Vaccine-based HIV Immunotherapy

Deal value of up to $785 million plus royalties

- Leverages Gritstone's vaccine platform technologies (adenoviral and samRNA)
- Based on preclinical data demonstrating strong, durable and broad anti-SIV CD8+ T cell responses and T cell memory data
- Gilead is conducting a Phase 1 study and is responsible for all R&D
- $40M milestone payment payable by Gilead for Phase 2 opt-in

Terms of Arrangement

GILEAD	gritstone bio
$60 million	Upfront payment
$725 million	Clinical, regulatory, and commercial milestones

Mid single-digit to low double-digit tiered royalties on net sales upon commercialization

Developing Next-Generation Vaccines for Oncology and Infectious Disease

Platforms Drive More Potent and Durable Immunity

- Best-in-class antigen prediction
- Proprietary, next-gen vectors drive response

Fully-integrated Biomanufacturing

Potential best-in-class neoantigen-based personalized cancer vaccine program (GRANITE) in randomized Phase 2/3 study for MSS-CRC

Self-amplifying mRNA (samRNA) candidate for COVID-19 in BARDA-funded, 10,000 subject Phase 2b randomized head-to-head study against currently-approved vaccine

Upcoming data readouts could de-risk clinical platforms and potentially enable expansion into additional disease types

Anticipated Upcoming Milestones

Additional data from COVID-19 Phase 1 studies (Oct 2023)
Preliminary data from Phase 2/3 GRANITE-1L study (1Q 2024)
Initiate Phase 2b head-to-head study in COVID-19 (1Q 2024)

Estimated Cash Runway into 4Q 2024*

**based on cash, cash equivalents, marketable securities, and restricted cash as of June 30, 2023 as well as estimated fees receivable and anticipated reimbursement of certain direct and indirect costs to Gritstone (during 4Q 2023 and the first half of 2024 under the BARDA Contract announced on September 27, 2023*



Thank You

ir@gritstone.com